Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.50 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 2/20 | 0.43 |
| ▸ | CTSE | P14091 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985753 | 0.90 | BACE1 (0.46) | BACE1BACE2RENAPPCTSD | |
| SCHEMBL2980865 | 0.85 | ALDH1A1 (0.46) | BACE1BACE2CTSDCTSECYP3A4 | |
| SCHEMBL2977803 | 0.85 | TP53 (0.45) | BACE1BACE2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2986525 | 0.83 | CYP3A4 (0.38) | BACE1BACE2CYP19A1CYP3A4CYP2C9 | |
| SCHEMBL2972544 | 0.82 | BACE1 (0.44) | BACE1BACE2RENAPPCTSD | |
| SCHEMBL2985847 | 0.81 | BACE1 (0.39) | BACE1BACE2CTSDCTSECYP3A4 | |
| SCHEMBL2980706 | 0.80 | ALDH1A1 (0.45) | BACE1CTSDCYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL2986897 | 0.80 | SMN1; SMN2 (0.50) | BACE1BACE2CTSDCTSECYP3A4 | |
| SCHEMBL2984449 | 0.78 | BACE1 (0.52) | BACE1BACE2RENAPPCTSD | |
| SCHEMBL2983179 | 0.77 | NPC1 (0.49) | MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786155-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-08-31 | — | — | US | disclosed |
| EP-2212295-A2 | 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050201-A2 | 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099244-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099244-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLC10A6, SLCO1B1 | BACE1 2113/4885BACE2 3063/4885REN 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.